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Disease-relatedworriesarefrequentlyreportedininﬂammatoryboweldisease(IBD),butlongitudinalassessmentsoftheseworries
are scarce. In the present study, patients completed the rating form of IBD patient concerns (RFIPC) at three occasions during one
year. One-way analysis of variance (ANO VA), t-tests, bivariate correlation, and linear regression analyses were used to analyse
data. The validity and reliability of the Norwegian RFIPC was tested. A total of 140 patients were included (V1), ulcerative colitis
(UC) n = 92, Crohn’s disease (CD) n = 48, mean age 46.9 and 40.0-year old, respectively. The highest rated worries included
having an ostomy bag, loss of bowel control, and reduced energy levels. Symptoms were positively associated with more worries.
A pattern of IBD-related worries was consistent over a period of one year. Worries about undergoing surgery or having an ostomy
bag seemed to persist even when symptoms improved. The Norwegian RFIPC is valid and reliable.
1.Introduction
In inﬂammatory bowel disease (IBD), comprising Crohn’s
disease (CD) and ulcerative colitis (UC), the measurement
of health-related quality of life (HRQOL) has become
important, both as a primary and secondary endpoint [1–4].
In IBD, the decrease in HRQOL scores is well documented
in a vast amount of studies [2–4]. Subjective health measure-
ments in patient research may reveal important issues for the
patient, but not apparent for the healthcare worker [1].
Inaccordancewithobservationsmadeinclinicalpractice
and with intention to help clinicians quantify information
about IBD- related worries, Drossman et al. [5] developed
the rating form of IBD patient concerns (RFIPC). Various
studies have made use of the RFIPC in clinical trials [5–
10]. These studies do, however, have a cross-sectional design,
which only provide a snapshot at a given point of time. Since
worries most often is future directed, they may potentially
change in time and space. Our knowledge of IBD-related
worries in a longitudinal perspective is limited. Only one
study addresses these issues prospectively in CD, but not in
UC [11]. Results of a longitudinal assessment of IBD-related
worries may facilitate patient-physician communication and
consequently be clinically impactful [1].
Diﬀerent studies have found the RFIPC to be valid and
reliable [5–10]. However, the RFIPC needs to be translated
and tested psychometrically in the Norwegian language to
overcome conceptual, semantic, and linguistic diﬀerences
across cultures and languages [1, 12].
The primary aim of this study was to assess disease-
related worries and concerns among IBD patients followed
prospectively for one year. Secondarily, we aimed to inves-
tigate whether IBD-related worries was associated with So-
ciodemographic and clinical data. In addition, we wanted
to evaluate the psychometric properties of the Norwegian
version of the RFIPC.2 Gastroenterology Research and Practice
2.MaterialsandMethods
2.1. Subjects. Participants were consecutively recruited from
three outpatient clinics in south-eastern Norway (the coun-
ties of Østfold and Hedmark) during routine follow-up
visits. Outpatient clinics usually get referred patients that
have poor disease control and need stabilisation, such as for
example, UC patients that are not maintaining remission
on 5-ASA or CD patients that have relapsed without any
current medical treatment. Patients treated with, for exam-
ple, azathioprine (AZA) or biologics, such as inﬂiximab
(remicade) or adalimumab (humira) are all followed by gas-
troenterologists at outpatient clinics. Participants recruited
intothisstudywhohadtobeaged18yearsoldorabove,with
previously veriﬁed IBD, either clinically, endoscopically, or
histologically, and without severe disease activity (deﬁned as
Simple (SCCAI clinical colitis activity index) [13]o rC r o h n ’ s
(Simple SCDAI disease activity index) [14] score under 10)
were eligible for inclusion in this study. The latter since
the aim of this study was solely to measure disease-related
worriesinpatientswhoseconditionhadstabilizedintoeither
remission, mild, or moderate disease activity. Patients were
excluded if they had cognitive impairment and were deemed
unlikely to comply with the study procedures or if they
participated in another study. At each centre, a consultant
gastroenterologist was in charge of the study protocol. The
inclusion period was from ultimo 2005 to primo 2007.
Sociodemographic, clinical, and patient reported outcome
(PRO) measures were collected from all patients at baseline
(V1)andafter1year(V3).Inordertoexaminethetest-retest
reliability of the RFIPC, patients from two out of the three
clinics (n = 71) were invited to ﬁll out the questionnaires a
second time after 6 months (V2).
2.2. Clinical and Sociodemographic Data. Sociodemographic
variables were gathered by interview, and data regarding
clinical status and symptoms were obtained through lab-
oratory tests, medical records, and disease activity indices
(SCCAI/SCDAI). In addition, we asked the patients to
complete a symptom-based questionnaire that graded their
self-perceived IBD symptoms during the previous 14 days
[3], using the following categories: no symptoms, mild
symptoms (did not interfere with everyday activities), mod-
erate symptoms (interfered with everyday activities and may
have resulted in sick leave), and severe symptoms (unable to
perform everyday activities, on sick leave or hospitalised).
Each patient’s phenotype was classiﬁed according to
the Vienna classiﬁcation for CD patients, as the Montreal
classiﬁcation did not exist when the study protocol was
designed. The UC patients were classiﬁed into three sub-
groups: proctitis, left-sided colitis (with inﬂammation up to
the splenic ﬂexure), and extensive colitis (with inﬂammation
beyond the splenic ﬂexure).
3. Questionnaires
3.1. The Rating Form of Inﬂammatory Bowel Disease Patient
Concerns(RFIPC). TheRFIPCisadisease-speciﬁcquestion-
naires developed by Drossman et al. [5]. This questionnaire
rates various important worries and concerns that are raised
by IBD patients. The questionnaire consists of the 25 most
frequently reported concerns reported by IBD patients,
with every item framed in the same style, for example,
“Because of your condition, how concerned are you with
...?” The responses were scored on a 100-mm horizontal
visual analogue scale (VAS). A score of 0-mm represents
no worries/concerns, and a score of 100-mm represents the
highest possible worries and concerns. The mean score of all
25 items yields the “sum score”.
3.2. Translation of the RFIPC Questionnaire. The forward
and backward translation was performed following general
guidelines [15, 16]. The RFIPC was translated from Amer-
ican English to Norwegian by two independent translators,
one gastroenterologist and one clinical research scientist,
both ﬂuent in English and with Norwegian as their native
tongue. After the two translations had been compared, a
preliminaryversionwasagreedupon.TheQuestionnairewas
then translated back into English by a professional translator
whose native language was English and who was unfamiliar
with the background objectives of the study. This translation
wasthencomparedtotheoriginalversion,andaﬁnalversion
of the questionnaire was agreed upon.
3.3. Short Form-36 (SF-36). The Short Form-36 (SF-36) is a
generic, self-administered questionnaire containing 36 items
[17] that are divided into 8 multi-item scales consisting of
physical functioning (PF), role physical (RP), bodily pain
(BP), general health (GH), vitality (VT), social functioning
(SF),roleemotional(RE),andmentalhealth(MH).Foreach
question, the raw score was coded and transformed into a
scale from 0 to 100, with 0 and 100 representing the lowest
and highest level of function, respectively. The SF-36 has
been validated by others [18].
3.4. Inﬂammatory Bowel Disease Questionnaire (N-IBDQ).
The IBDQ is a disease-speciﬁc questionnaire developed by
Irvine et al. [19, 20]. The original version consists of 32
itemsthataredividedintofourdimensions:bowelsymptoms
(e.g., loose stools or abdominal pain), systemic symptoms
(e.g., fatigue or altered sleep patterns), social function (e.g.,
work attendance), and emotional function (e.g., anger or
depression). The Norwegian validation study (N-IBDQ)
revealed a ﬁve-dimensional structure: emotional function-
1 (EF-1) (fatigue, energy), bowel function-1 (B1) (stool
consistency and pattern), bowel function-2 (B2) (bowel pain
and discomfort), social function (SF) (work attendance,
cancelling social events), and emotional function-2 (E2)
(Worries) [4]. All of the responses were scored on a 7-point
Likert scale, with a score of 7 representing no problems
and a score of 1 representing severe problems. This gives a
possible score range of 32–224, with higher scores reﬂecting
an improved HRQOL [4, 19, 20].
4.StatisticalMethods
Descriptive analyses were performed using descriptive statis-
tics, t-test and one-way ANOVA. Associations betweenGastroenterology Research and Practice 3
Table 1: Primary Sociodemographic and clinical data at study entry (V1).
UC (n = 92) CD (n = 48)
Age (mean) (SD) 46.9 (5.8) 40.0 (15.0)
Age range 20–82 19–69
Gender
Female 43 (47) 36 (75)
Male 49 (53) 12 (25)
Educational level
Second level, ﬁrst stage (lower) 16 (17.4) 5 (10.4)
Second level, second stage (medium) 42 (45.7) 22 (45.8)
Third level (university) 34 (37.0) 21 (43.8)
Smoking (yes) 23 20
Civil status
Single 15 (16.3) 10 (21)
Married/cohabitant 70 (76.1) 34 (71)
Divorced/separated 3 (3.3) 3 (6)
Widow/widower 4 (4.3) 1 (2)
Disease duration yrs mean (SD) 8.5 (9.5) 9.2 (9.6)
Abbreviations: UC: ulcerative colitis, CD: Crohn’s disease. Figures are in numbers and (%), if not otherwise noted.
clinical/epidemiological data and RFIPC scores were tested
with a t-test for binary variables; otherwise, bivariate cor-
relation analyses were used. Factors signiﬁcantly associated
with RFIPC outcome were entered into a linear regression
analysis.
The validity and reliability of the Norwegian RFIPC was
tested following recommendations in the literature [1, 21].
The responsiveness of the RFIPC was calculated through
the change of perceived IBD symptoms [5]f r o mV 1t oV 2 .
Both a paired t-test and Cohen’s d were used. Scores of 0.2,
0.5, and 0.8 were regarded as small, medium, and large eﬀect
sizes, respectively [22].
All tests were two-sided and used a 5% signiﬁcance level.
All data was analysed using SPSS v.17 and v.18 (IBM Inc,
Somers, US).
5. Ethical Considerations
The study was performed in accordance with the principles
of the Helsinki declaration, and approval was obtained from
the Regional Ethics Committee and the Norwegian Data
Inspectorate before the study was commenced.
6. Results
One hundred and forty four patients diagnosed with either
UC or CD gave written informed consent for participation
in the study. One patient was excluded due to severe disease
activity at inclusion (SCDAI > 10), one patient withdrew
from the study after a few weeks, and two patients were
excluded due to incomplete responses to the questionnaires.
Atotalof140patients(UC, n =92;CD,n =48)hadsuﬃcient
data for statistical analysis at the baseline. Of patients invited
to attend the 6 months (V2) and one year (V3) follow-up
visits; 63 out of 71 (UC, n = 42; CD, n = 21) and 133 out of
140 (UC, n = 86; CD, n = 47) participated, respectively. At V2
and V3, all patients had suﬃcient data for statistical analysis.
6.1. Sociodemographic and Clinical Data. Primary Sociode-
mographic and clinical data at study entry are presented
in Table 1. The mean SCCAI for UC patients was 2.79 (SD
2.39) and 2.35 (SD 2.40) at V1 and V3, respectively. The
comparable number in SCDAI for CD patients was 3.9 (SD
2.7) and 3.8 (SD 3.0) at V1 and V3, respectively. In the last
year prior to entry, the number of UC and CD patients who
had experienced a relapse was 57% and 50%, respectively.
The disease activity indices did not diﬀer signiﬁcantly from
V1 to V3 in UC or CD patients (P = 0.22 and P = 0.86,
respectively). Moreover, there were no signiﬁcant diﬀerences
in patients reporting no, mild, moderate, or severe IBD
symptoms from V1 to V3. In UC however, there were
numerically more women than men who reported their
IBD symptoms to be improved from V1 to V3, but these
diﬀerences were not signiﬁcant.
6.2. Scale Statistics and Impact of Clinical/Epidemiological
Data. The mean (SD) RFIPC sum score was 29.0 (17.3)
and 27.2 (19.5) for UC patients at V1 and V3, respectively.
The comparable numbers for CD patients were 32.2 (18.8)
and 32.4 (21.9). There were no signiﬁcant diﬀerences in the
RFIPC sum score for the UC or CD patients at baseline (V1)
or after one year (V3). The CD patients had numerically
higher mean RFIPC sum scores than UC patients at all visits,
but these diﬀerences were not statistically signiﬁcant. The
numerical ranking of individual RFIPC items at V1 and V3
is presented in Table 2. The change in numerical rankings of
RFIPC items from V1 to V3 was marginal for both UC and
CD patients. Worries about “having an ostomy bag, energy
level, loss of bowel control, passing the disease on to the
children and developing cancer” were the ﬁve worries rated4 Gastroenterology Research and Practice
Table 2: Numerical ranking of disease-related worries and concerns among IBD patients followed for 1-Year (items ranked as the ﬁve most
important are in boldface).
RFIPC item UC CD
V1 (n = 92) V3 (n = 86) V1 (n = 48) V3 (n = 47)
Financial diﬃc u l t i e s 1 81 81 72 3
Pain and suﬀering 16 13 12 12
Ability to achieve full potential 10 7 8 8
Loss of bowel control 5321
Developing cancer 2246
Dying early 12 10 7 7
Being a burden on others 6 5 9 3
Attractiveness 21 16 18 17
F e e l i n g a l o n e 2 21 92 32 2
Feeling out of control 11 9 10 9
Feeling dirty and smelly 19 21 16 16
Ability to perform sexually 20 22 21 19
Ability to have children 25 25 25 25
Passing the disease on to your children 3454
Being treated as diﬀerent 24 24 24 24
Having surgery 8 12 6 11
Having an ostomy bag 1115
Producing unpleasant odors 13 20 14 14
Energy level 4 6 32
Feelings about my body 15 15 19 15
Intimacy 23 23 22 21
Loss of sexual drive 17 17 15 18
Having access to quality medical care 14 14 20 20
Uncertain nature of my disease 7 8 11 13
Eﬀects of medication 9 11 13 10
AbbreviationsIBD:inﬂammatoryboweldisease,V1:visit1(baseline),V3:visit3(1-Year),RFIPC:ratingformofinﬂammatoryboweldiseasepatientconcerns,
UC: ulcerative colitis, and CD: Crohn’s disease.
as most important regardless of diagnosis and visit number.
In addition, worries about “being treated as diﬀerent” and
“ability to have children” were ranked least important at all
visits for both UC and CD, with ﬂoor eﬀects of 16.9 and
30.3%, respectively. “Ability to have children” was associated
with younger age and the female gender. There were no
signiﬁcant diﬀerences in mean RFIPC sum score at neither
V1 nor V3 between patients who either had or had not
experienced a relapse in the year prior to entry, regardless
of diagnosis. The numerical ranking of RFIPC items was also
similar in this respect. When diﬀerentiating between patients
reporting no, mild, moderate, and severe IBD symptoms, the
patterns of worries were almost identical for both UC and
CD. However, numerical scores on the RFIPC VAS increased
successively with increased symptoms (Table 3).
In CD patients, we did not ﬁnd any associations between
the RFIPC sum scores and Sociodemographic and clinical
data neither at V1 or V3. In UC as in CD, there were limited
associations between Sociodemographic, clinical data and
RFIPC sum scores. Increasing IBD symptoms was found to
be the only factor of inﬂuence on RFIPC sum scores among
UC patients at both V1 and V3 (P<0.01).
6.3. Validity, Reliability, and Responsiveness of the RFIPC.
Factoranalysis(maximumlikelihoodmethod)performedon
the RFIPC items at baseline resulted in the extraction of six
factors explaining 70% of the total variance. This was also
reproduced when analysing each diagnosis separately. Factor
loadings are presented in Table 4.
Spearman’s correlation coeﬃcients were calculated
between the RFIPC subscales and the domains of N-
IBDQ and SF-36, respectively. As expected, we found
moderate-to-high correlations between the RFIPC and the
psychological, social, and mental domains of N-IBDQ/SF-
36. The correlations were generally lowest in the physical
HRQOL dimensions.
The Cronbach’s alpha coeﬃcient, which measures inter-
nal consistency reliability, was found to be 0.94, indicating
that the intercorrelation of items in the RFIPC was very good
and consequently measured the same construct. There were
only eight and fourteen patients in the CD and UC group,
respectively, who reported their condition to be unchanged
from V1 to V2. Thus the test-retest reliability results are
presented together in Table 5, as the groups showed a similar
pattern. The intraclass correlation coeﬃcient (ICC) is usedGastroenterology Research and Practice 5
Table 3: Determination of the RFIPC’s ability to discriminate between IBD symptom severity scores at baseline.
UC (n = 92)
None Mild Moderate/severe F-value P-value
RFIPC dimensions
F1 Impact of disease 15.5 (12.6) 29.1 (20.0) 43.2 (18.8) 14.895 <0.001
F2 Expectancy 23.5 (17.1) 40.6 (26.0) 44.6 (24.9) 5.584 0.005
F3 Treatment 15.7 (11.2) 34.5 (23.1) 42.6 (25.7) 10.082 <0.001
F4 Intimacy 9.4 (9.6) 21.4 (17.4) 28.1 (24.4) 6.723 0.002
F5 Stigma 11.0 (13.0) 21.1 (22.1) 29.6 (22.7) 5.205 0.007
F6 Complications 15.8 (15.1) 30.2 (15.6) 38.0 (17.8) 4.142 0.019
Sum score 16.0 (11.3) 30.2 (15.6) 38.0 (17.8) 13.165 <0.001
CD (n = 48)
None Mild Moderate/severe F-value P-value
RFIPC dimensions
F1 Impact of disease 28.5 (25.1) 31.7 (19.0) 44.6 (19.1) 2.633 NS
F2 Expectancy 38.8 (36.4) 41.4 (26.7) 44.2 (29.1) .102 NS
F3 Treatment 34.3 (33.3) 28.9 (18.6) 30.7 (22.4) .176 NS
F4 Intimacy 19.1 (28.1) 20.6 (19.9) 27.2 (26.7) .489 NS
F5 Stigma 16.8 (29.4) 26.4 (23.6) 21.2 (19.2) .597 NS
F6 Complications 28.0 (28.7) 30.8 (20.8) 23.1 (20.7) .572 NS
Sum score 28.6 (26.3) 31.4 (16.6) 35.1 (18.8) .377 NS
Abbreviations: RFIPC: rating form of inﬂammatory bowel disease patient concerns, F1:F6 (Factors 1–6), UC: ulcerative colitis, CD: Crohn’s disease.F i g u r e s
are presented as means and standard deviations.
to quantify the degree to which individual RFIPC scores at
V 1a n dV 2r e s e m b l ee a c ho t h e r .As c o r eo f0a n d1r e p r e s e n t s
no and high reliability, respectively. We found ICC’s in our
study indicating high reliability.
Twenty-two patients reported their IBD condition to be
unchangedatV2.Becausethesamepatternofresponsiveness
was observed when analysing UC and CD patients separately
(data not shown), we chose to report the data together in
Table 6. Overall, responsiveness of the RFIPC was good.
7. Discussion
I B Di sc h a r a c t e r i s e db ys y m p t o m s ,s u c ha sf r e q u e n tb o w e l
movements, abdominal pain, and rectal bleeding, that cycle
between remission and exacerbation. These symptoms may,
in conjunction with psychosocial factors, result in secondary
consequences such as impaired health-related quality of life
(HRQOL) and increased fatigue [2–4, 23].
Even though, worries can be regarded as a normal
feature of life, we are frequently confronted with IBD-related
worriesandconcernsreportedbypatientsinclinicalpractice.
The RFIPC was developed to help clinicians obtain and
quantify this kind of information [5]. This is the ﬁrst study
t or e p o r tt h ew o r r i e sa n dc o n c e r n so fb o t hU Ca n dC D
patients in a prospective, longitudinal perspective. Blondel-
Kucharski et al. [11] used the RFIPC to study worries of CD
patients followed for one year. However, they included both
in- and outpatients, and, consequently, the participants are
quite heterogeneous. In the present study, we included only
outpatientswithoutseveredisease.Ourﬁndingsindicatethat
the pattern of worries in IBD is relatively consistent over a
pe ri odo fo n ey e a rH o w ev e r ,t h el ev elo fw o rri e s ,a sm e a s u r ed
with the RFIPC, increased successively with IBD symptoms.
The level of worrying as well as the numerical ranking of
worries seem also to be unrelated to having experienced a
relapse in the past year. These ﬁndings may indicate that it
is the current IBD symptoms that are important for the level
of worrying and not a history of serious events in the past.
The pattern of worries found in our study also seems to be in
accordance with the ﬁndings of cross-sectional studies that
have used the RFIPC [5–11].
The potential need of having an ostomy bag was rated
as the most important worry by UC patients. A possible
explanation may be linked to the dramatic consequence that
an ostomy bag may have on daily living and body image. In
CD, loss of bowel control was rated as most important. At
theopposite endofthespectrum,“being treatedasdiﬀerent”
and “the ability to have children” were rated least important
at all of the visits, regardless of diagnosis. Having a chronic
condition like IBD may potentially result in a wide range
of environmental responses. However, our ﬁndings indicate
that neither UC nor CD patients are particularly worried
that they will be stigmatised by their social environments.
Similar ﬁndings have been reported in other studies [5, 6].
Fertility may be inﬂuenced by disease activity, surgery, and
medications[24].Thereisalsoariskofadverseeventsduring
pregnancy[24].However,wedidﬁndthatthe“abilitytohave
children” is rated least important among all 25 RFIPC items.
One possible explanation may be that this item is unsuitable
for use in studies covering a wide range of age groups,
because this issue probably is of greater concern to patients
in their twenties than to patients in their sixties. Indeed, this6 Gastroenterology Research and Practice
Table 4: Factor analysis of the RFIPC using maximum likelihood method.
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
Impact of disease
(1) Financial diﬃculties 0.59
(2) Pain or suﬀering 0.60
(3) Ability to achieve full potential 0.68
(4) Loss of bowel control 0.46
(9) Feeling alone 0.47
(10) Feeling out of control 0.53
(19) Energy level 0.71
Expectancy
(5) Developing cancer 0.72
(6) Dying early 0.82
(7) Being a burden on others 0.48
(14) Passing the disease to your children 0.50
Treatment
(23) Having access to quality medical care 0.66
(24) Uncertain nature of my disease 0.73
(25) Eﬀects of medication 0.74
Intimacy
(12) Ability to perform sexually 0.63
(21) Intimacy 0.86
(22) Loss of sexual drive 0.64
Stigma
(11) Feeling dirty or smelly 0.74
(18) Producing unpleasant odors 0.77
(15) Being treated as diﬀerent 0.41
Complications
(16) Having surgery 0.61
(17) Having an ostomy bag 0.92
(8) Attractiveness (0.34)
(13) Ability to have children (0.16)
(20) Feelings about my body (0.39)
is underlined by the fact that more worries of this item were
associated with both a younger age and the female gender.
TheonlyfactorinUCpatientsthatseemstobeassociated
with higher levels of worry over time is the presence of IBD
symptoms. Our ﬁndings indicate that worries are closely
correlatedwiththediseasecourse.Thiscausalityissupported
by the test-retest analysis between V1 and V2. Worries
related to undergoing surgery or having an ostomy bag
(factor six) seems to be relatively consistent even when IBD
symptoms improve. However, worries do increase when the
IBD condition deteriorates [5, 11]. However, Hjortswang
et al. [7] reported weak correlations between the number
of daily stools and overall RFIPC outcome in his study of
Swedish UC patients. In CD patients, we were not able to
predict RFIPC outcome at V1 or V3, which may be a result
of type 2 statistical errors.
IntheRFIPC,thenumberoffactorsdiﬀersacr ossvarious
studies; in addition, there are discrepancies in the RFIPC
items that relate to various factors [5–11]. We found 6
factors that add further complexity to the scaling of the
RFIPC. In particular, these variations limit the possibility
of comparison across studies and, potentially, the use of
RFIPC in clinical trials. Only one of our factors (Factor four;
intimacy) was identical to a factor in the original validation
by Drossman et al. [5] (Factor two; sexual intimacy). The
need of standardisation in health-related quality of life
questionnaires has also been put forward in a recent review
[25]. The use of the same questionnaires in diﬀerent studies
does not necessarily guarantee comparable results due to
diﬀerent questionnaire versions, translations, and methods
of computing and presenting the data.
One possible solution to the problem of comparability
is to use the RFIPC sum score of all 25 items. This method
has been applied in several studies using the RFIPC [26]. We
found mean sum scores at baseline to be lower than those
reported by Drossman et al. [5], but higher than the resultsGastroenterology Research and Practice 7
Table 5: Test-retest reliability with intraclass correlation coeﬃcients (ICC) in patients reporting no change in their condition from baseline
to followup after 6 months.
V1 mean (SD) V2 mean (SD) Mean Diﬀerence (95% CI) ICC
RFIPC factors
Impact of disease 37.2 (22.4) 35.8 (22.0) 1.4 .90
Expectancy 48.2 (29.3) 44.8 (29.1) 3.4 .88
Treatment 30.2 (27.6) 29.3 (25.2) 0.9 .83
Intimacy 21.8 (20.4) 20.5 (25.6) 1.3 .89
Stigma 32.3 (28.2) 29.6 (28.0) 2.7 .83
Complications 29.9 (22.4) 24.7 (32.9) 5.2 .79
Sum score 35.2 (20.2) 33.2 (21.2) 2.0 .98
Abbreviations: RFIPC: rating form of IBD patient concerns, V1: baseline,V2: 6 months.
Table 6: Comparison of scores at V1 and V2 in patients reporting improvement or deterioration of IBD symptoms. Eﬀect-size calculated
with Cohen’s d.
n V1 V2 Diﬀerence (95% CI) Cohen’s d P value
Improvement of symptoms mean (SD)
F1 Impact of disease 22 45.4 (18.9) 26.6 (17.2) 18.7 (12.6–24.9) 1.04 <0.001
F2 Expectancy 22 49.1 (22.6) 31.2 (24.5) 17.9 (8.8–27.0) 0.75 0.002
F3 Treatment 22 48.4 (24.3) 23.1 (18.6) 25.4 (15.0–35.8) 1.16 0.049
F4 Intimacy 22 32.5 (25.5) 18.7 (23.0) 13.8 (6.1–21.6) 0.56 <0.001
F5 Stigma 22 34.5 (23.1) 19.2 (17.9) 15.3 (6.4–24.2) 0.74 0.009
F6 Complications 22 33.9 (21.7) 29.8 (25.2) 4.0 (−7.9–16.0) 0.17 0.112
Sum score 22 41.3 (15.7) 24.2 (16.6) 17.1 (12.0–22.3) 1.05 <0.001
Deterioration of symptoms mean (SD)
F1 Impact of disease 19 27.8 (16.3) 42.3 (20.8) 14.5 (20.4–8.5) −0.77 <0.001
F2 Expectancy 19 44.8 (27.0) 51.9 (24.8) 7.1 (13.9–.3) −0.27 <0.001
F3 Treatment 19 32.5 (22.4) 44.0 (23.8) 11.6 (22.3–.9) −0.49 0.017
F4 Intimacy 19 25.0 (22.7) 35.6 (22.2) 10.5 (21.0–.1) −0.47 0.018
F5 Stigma 19 20.1 (16.7) 33.9 (25.7) 13.8 (23.1–4.6) −0.63 0.002
F6 Complications 19 29.5 (20.0) 61.7 (21.5) 32.2 (42.6–21.8) −1.55 <0.001
Sum score 19 31.7 (17.6) 42.3 (19.3) 10.6 (16.7–4.5) −0.57 <0.001
Abbreviations: F1–F6: rating form of IBD patient concerns, factors 1–6. V1: baseline, V2: 6-months followup.
from studies performed in Sweden [6, 7]. However, the wide
use of sum scores for the comparison of RFIPC results has
beencriticised[26].Thesumscoreimpliesthatoneconsiders
speciﬁc worries and concerns to be part of one general
underlying dimension, which is debateable [26]. Another
usefulmethodistoreporttheresultsoftheindividualRFIPC
items, as we do in this study. To be able to address IBD-
related worries in clinical practice, it is essential to know
speciﬁcally what patients worry about.
The reliability of the RFIPC was found to be high, with
an ICC of 0.98 (RFIPC sum score) and a Cronbach’s alpha
of 0.94; this is in accordance with previous validations [5–7].
Our ﬁndings also indicate that the RFIPC is able to detect
changes over time and, consequently, is suitable for use in
longitudinal evaluations [27].
In conclusion, patients with IBD seem to experience
the same pattern of disease-related worries when followed
prospectivelyoveraone-yearperiod.Higherlevelsofworries
are associated with increased IBD symptoms. In addition,
worries about undergoing surgery or having an ostomy bag
seem to persist even when IBD symptoms improve. Finally,
we have demonstrated the Norwegian RFIPC to be valid and
reliable.
Disclosure
The authors of this paper declare that this paper is submitted
solely to Gastroenterology Research and Practice.
Conﬂict of Interests
The authors declare no conﬂict of interests.
Acknowledgments
The authors wish to thank Professor Dr.Philos Leiv Sandvik,
University of Oslo, for statistical guidance. Furthermore,
The authors wish to thank Hilde Næs, Brita Olafsen,
Margrethe Solheim, and Marita Nilsen for their contribution
in gathering data for this study. Østfold Hospital Trust,8 Gastroenterology Research and Practice
Oslo University Hospital, and the University of Oslo are
acknowledged for contributing funds to this study.
References
[1] P. M. Fayers and D. Machin, Quality of Life: The Assessment,
Analysis and Interpretation of Patient-Reported Outcomes,J o h n
Wiley & Sons, Chichester, UK, 2007.
[2] T. Bernklev, J. Jahnsen, E. Aadland et al., “Health-related qual-
ity of life in patients with inﬂammatory bowel disease ﬁve
years after the initial diagnosis,” Scandinavian Journal of
Gastroenterology, vol. 39, no. 4, pp. 365–373, 2004.
[3] T. Bernklev, J. Jahnsen, I. Lygren, M. Henriksen, M. Vatn,
and B. Moum, “Health-related quality of life in patients with
inﬂammatory bowel disease measured with the short form-
36: psychometric assessments and a comparison with general
population norms,” Inﬂammatory Bowel Diseases, vol. 11, no.
10, pp. 909–918, 2005.
[4] T. Bernklev, B. Moum, and T. Moum, “Quality of life in
patients with inﬂammatory bowel disease: translation, data
quality, scaling assumptions, validity, reliability and sensitivity
to change of the Norwegian version of IBDQ,” Scandinavian
Journal of Gastroenterology, vol. 37, no. 10, pp. 1164–1174,
2002.
[5] D. A. Drossman, J. Leserman, Z. Li, C. M. Mitchell, E. A.
Zagami, and D. L. Patrick, “The rating form of IBD patient
concerns: a new measure of health status,” Psychosomatic
Medicine, vol. 53, no. 6, pp. 701–712, 1991.
[6] H. Stjernman, C. Tysk, S. Almer, M. Str¨ om, and H.
Hjortswang, “Worries and concerns in a large unselected
cohort of patients with Crohn’s disease,” Scandinavian Journal
of Gastroenterology, vol. 45, no. 6, pp. 696–706, 2010.
[7] H. Hjortswang, M. Str¨ om, R. T. Almeida, and S. Almer,
“Evaluation of the RFIPC, a disease-speciﬁc health-related
quality of life questionnaire, in Swedish patients with ulcer-
ative colitis,” Scandinavian Journal of Gastroenterology, vol. 32,
no. 12, pp. 1235–1240, 1997.
[8] J. F. Colombel, Y. Yazdanpanah, F. Laurent, P. Houcke, N.
Delas, and P. Marquis, “Qualit´ e de vie dans les maladies
inﬂammatoires chroniques de l’intestine,” Gastroent´ erologie
Clinique et Biologique, vol. 20, no. 12, pp. 1071–1077, 1996.
[9] E. C. Rooy, B. Toner, R. G. Maunder et al., “Concerns of
patients with inﬂammatory bowel disease: results from a
clinical population,”AmericanJournal of Gastroenterology, vol.
96, no. 6, pp. 1816–1821, 2001.
[10] S. Levenstein, Z. Li, S. Almer et al., “Cross-cultural variation
indisease-relatedconcernsamongpatientswithinﬂammatory
bowel disease,” American Journal of Gastroenterology, vol. 96,
no. 6, pp. 1821–1830, 2001.
[11] F. Blondel-Kucharski, C. Chircop, P. Marquis et al., “Health-
related quality of life in Crohn’s disease: a prospective
longitudinal study in 231 patients,” American Journal of
Gastroenterology, vol. 96, no. 10, pp. 2915–2920, 2001.
[12] F. Guillemin, C. Bombardier, and D. Beaton, “Cross-cultural
adaptation of health-related quality of life measures: literature
review and proposed guidelines,” Journal of Clinical Epidemi-
ology, vol. 46, no. 12, pp. 1417–1432, 1993.
[ 1 3 ] R .S .W a l m s l e y ,R .C .S .A y r e s ,R .E .P o u n d e r ,a n dR .N .A l l a n ,
“A simple clinical colitis activity index,” Gut,v o l .4 3 ,n o .1 ,p p .
29–32, 1998.
[14] R. F. Harvey and J. M. Bradshaw, “A simple index of Crohn’s
disease activity,” The Lancet, vol. 1, no. 8167, p. 514, 1980.
[15] D. R. Streiner and G. R. Norman, “Devising the items,”
in Health Measurement Scales: A Practical Guide to Their
Developement, D. L. Streiner and G. R. Norman, Eds., pp. 15–
27, Oxford University Press, New York, NY, USA, 1995.
[16] J. E. Ware, P. Gandek, S. D. Keller, and IQOLA Group, “Eval-
uating instruments used cross-nationally: methods from the
IQOLA project,” in Quality of Life and Pharmaeconomics in
Clinical Trials, B. Spilker, Ed., pp. 681–692, Lippincott-Raven
Press, Philadelphia, Pa, USA, 1996.
[17] J. E. Ware and C. D. Sherbourne, “The MOS 36-item short-
form health survey (SF-36). I. Conceptual framework and
itemselection,”MedicalCare,vol.30,no.6,pp.473–483,1992.
[18] J. H. Loge and S. Kaasa, “Short form 36 (SF-36) health survey:
normative data from the general Norwegian population,”
ScandinavianJournalofSocialMedicine,vol.26,no.4,pp.250–
258, 1998.
[19] G. Guyatt, A. Mitchell, E. J. Irvine et al., “A new measure of
health status for clinical trials in inﬂammatory bowel disease,”
Gastroenterology, vol. 96, no. 3, pp. 804–810, 1989.
[20] E. J. Irvine, B. Feagan, J. Rochon et al., “Quality of life:
a valid and reliable measure of therapeutic eﬃcacy in the
treatment of inﬂammatory bowel disease. Canadian Crohn’s
relapse prevention trial study group,” Gastroenterology, vol.
106, no. 2, pp. 287–296, 1994.
[21] J.Dawson,H.Doll,R.Fitzpatrick,C.Jenkinson,andA.J.Carr,
“The routine use of patient reported outcome measures in
healthcare settings,” British Medical Journal, vol. 340, article
c186, 2010.
[22] J.Cohen,StatisticalPowerAnalysisfortheBehaviouralSciences,
Lawrence Erlbaum Associates, Mahwah, NJ, USA, 1988.
[ 2 3 ]L .P .J e l s n e s s - J ø r g e n s e n ,T .B e r n k l e v ,M .H e n r i k s e n ,R .T o r p ,
and B. A. Moum, “Chronic fatigue is more prevalent in
patients with inﬂammatory bowel disease than in healthy
controls,”InﬂammatoryBowelDisease,vol.17,no.7,pp.1564–
1572, 2011.
[24] U. Mahadevan, “Fertility and pregnancy in the patient with
inﬂammatory bowel disease,” Gut, vol. 55, no. 8, pp. 1198–
1206, 2006.
[25] M. L. Høivik, T. Bernklev, and B. Moum, “Need for standard-
ization in population-based quality of life studies: a review of
the current literature,” Inﬂammatory Bowel Diseases, vol. 16,
no. 3, pp. 525–536, 2010.
[26] S. J¨ aghult, F. Saboonchi, U. B. Johansson, R. Wredling, and
M. Kapraali, “Factor structures of the Swedish version of the
RFIPC: investigating the validity of measurements of IBD
patient’sworriesandconcerns,”GastroenterologyResearch,vol.
3, no. 5, pp. 191–200, 2010.
[27] G. H. Guyatt, R. A. Deyo, M. Charlson, M. N. Levine, and
A. Mitchell, “Responsiveness and validity in health status
measurement:aclariﬁcation,”JournalofClinicalEpidemiology,
vol. 42, no. 5, pp. 403–408, 1989.